JSR Life Sciences Expands Amsphere™ A3 Production Capacity

Tokyo, Japan - May 9, 2017 – JSR Life Sciences (JLS), the global life sciences focused division of JSR Corporation, today announced plans for expansion of its production capabilities of Amsphere™ A3 protein-A chromatography resin at JSR’s Belgium subsidiary, JSR Micro NV. This expansion will effectively increase its production capacity by 6 times and provide all-important redundancy in its manufacturing capability. 

JLS’s Amsphere™ A3 has experienced rapid adoption as an alkali-stable, high-capacity alternative option for downstream purification in the biopharmaceutical industry since its launch in January 2016.  Based on that success and growing demand, JLS has implemented a business continuity strategy that includes multiple location manufacturing to ensure both critical material supply to the global biopharmaceutical market and additional scale capabilities. 

JSR chose to expand in Belgium because of the extensive biochemistry and ligand manufacturing expertise already in place at JSR Micro NV as well as the significance of the European market. Phase one of the expansion construction started earlier this year with plans to be fully operational in 2018. The multi-phased expansion plan will keep pace with the growing demand for JLS’s Amsphere™ A3, with the total additional capacity completed by the end of the company’s fiscal year 2019.

Read full press release